Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2007-11-27

Clinical Trial Update: The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of irbesartan at 150/12.5 mg and 300/25 mg in patients with mild hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Irbesartan (irbesartan)

Snippet

Sponsor: Sanofi | Conditions: Hypertension | Phase 4 | Status: COMPLETED